Patent · US Active

Agonistic anti TNFR2 antibody molecules

US12139547B2 · kind B2 · utility

0Cited by

1References

29Claims

0Family size

Assignee

BIOINVENT INTERNATIONAL AB · SE

Inventors

Björn Frendéus · Landskrona, SE
Ingrid Teige · Lund, SE
Linda MÅRTENSSON · Bjärred, SE
Petra HOLMKVIST · Strada a scorrimento veloce Trapani-Marsala, SE
Monika SEMMRICH · Malmö, SE

Key dates

Filing date	Nov 1, 2019
Grant date	Nov 12, 2024
Priority date	—
Expiry date	Sep 19, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.